Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Glimepiride (2mg) + Metformin (500mg) SR + Voglibose (0.2mg) Bilayered Smart Tablet
Therapeutic Category
Antidiabetic, Diabetic, Endocrinology
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10*15
Price
₹186/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Vogliviga GM2/0.2 is a bilayered smart tablet designed for the effective management of type 2 diabetes mellitus. This formulation combines three active ingredients: Glimepiride (2 mg), Metformin (500 mg) sustained release (SR), and Voglibose (0.2 mg). Each component plays a crucial role in controlling blood glucose levels, making this medication a comprehensive option for patients struggling with diabetes. Glimepiride, a sulfonylurea, stimulates the pancreas to release insulin, thereby lowering blood sugar levels. Metformin, a biguanide, enhances insulin sensitivity and reduces hepatic glucose production, contributing to better glycemic control. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, further aiding in the management of postprandial blood glucose spikes. Together, these ingredients work synergistically to provide a robust approach to diabetes management.
Vogliviga GM2/0.2 is a bilayered smart tablet designed for the effective management of type 2 diabetes mellitus. This formulation combines three active ingredients: Glimepiride (2 mg), Metformin (500 mg) sustained release (SR), and Voglibose (0.2 mg). Each component plays a crucial role in controlling blood glucose levels, making this medication a comprehensive option for patients struggling with diabetes.
Glimepiride, a sulfonylurea, stimulates the pancreas to release insulin, thereby lowering blood sugar levels. Metformin, a biguanide, enhances insulin sensitivity and reduces hepatic glucose production, contributing to better glycemic control. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, further aiding in the management of postprandial blood glucose spikes. Together, these ingredients work synergistically to provide a robust approach to diabetes management.
Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain. Hypoglycemia may occur, especially if meals are skipped or if the patient engages in excessive physical activity.
Vogliviga GM2/0.2 is indicated for the treatment of type 2 diabetes mellitus, particularly in patients who require multiple mechanisms of action to achieve optimal glycemic control.
Consult your healthcare provider before starting this medication, especially if you have a history of kidney or liver issues.
Store Vogliviga GM2/0.2 tablets in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children.
Composition : Amlodipine 10 mg Tablet
Composition : Amlodipine 2.5 mg Tablet
Composition : Apixaban 5 MG Tablet
Composition : Atenolol 50 MG Tablet
Composition : Benidipine 4mg + Telmisartan 40mg Tablet
Composition : Azelnidipine 8mg Tablet
Composition : Bisoprolol 5mg + Amlodipine 5mg Tablet
Composition : Bisoprolol 1.25 MG Tablet
Composition : Carvedilol 12.5 tablet
Composition : Carvedilol CR 10mg Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This triple anti-diabetic combination is widely used in type 2 diabetes management, making it a strong prescription product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand in type 2 diabetes, post-meal blood sugar control, fasting glucose control, insulin resistance, and long-term glycemic management. It is widely prescribed by physicians and diabetologists for patients requiring multi-mechanism therapy for better sugar control.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Glimepiride 2mg + Metformin 500mg SR + Voglibose 0.2mg Bilayered Smart Tablet with monopoly rights, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from strong chronic prescription demand, lifelong therapy usage, and steady monthly repeat sales in diabetes care when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this diabetic formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.